QMS Medi cut its service margin guidance in half. It once said margins were 50%+.
Medical-camp operator told investors its core growth engine earns 25% EBITDA, not the 50%+ it cited in 2023. Camp cost structure also changed.
What's new
- Service segment EBITDA margin is 25%, down from the 50%+ management cited in Aug 2023.
- Some camps now use a variable per-patient cost model, contradicting the earlier fixed-cost assurance.
- FY27 EBITDA margin guidance narrowed to 18-19%, below the 17% target management gave for FY26.
Themes from the call
Margins
Service margin cut to 25% from 50%+ is the single biggest valuation change this call produced.
Camp economics
Variable cost model in some camps introduces turnout risk that management previously ruled out.
Growth
Service revenue is doubling to ₹100 cr in FY27 on signed contracts, so scale is real even if margins halved.
Guidance watch
- FY27 revenue ₹206 cr reaffirmed; service revenue to double to ~₹100 cr; EBITDA margin 18-19%.
- Camp revenue target ₹18-20 cr (40-54% growth) through 4,500-5,000 camps.
- Product segment FY27 growth 10-15%, contingent on supply chain recovery.
Risk flags
- A 50% margin cut on the high-growth segment is a structural change, not a one-off. Long-term margin models need a rethink.
- Variable camp cost model means patient turnout now matters, a risk management previously said didn't exist.
- FY26 EBITDA margin landed at 15%, missing management's own 17% guidance.
Key quotes
-
"If you are asking me about the camps and all margins, in the camps and these education business margins are very high. It's almost around 50% plus margins."
— QMS Medi management, Aug 2023 call -
"The entire service segment margin is around 25%."
— QMS Medi management, Jun 2026 call
The brief
QMS Medi's service segment, the growth engine it once told analysts earns 50%+ EBITDA, now earns 25%. That halving is not a blip. It is a structural revision to the unit economics underpinning the stock's valuation. Management framed it as a permanent segment-level margin, not a cyclical trough. The second credibility hit lands on camps. Management previously said camp costs were fixed regardless of patient turnout. This quarter it acknowledged some camps operate on variable per-patient models. Turnout risk exists where management said it didn't. On the operational side, the business is real. Service revenue hit ₹50 cr in FY26 and management wants ₹100 cr in FY27 on signed contracts like the Humrahi program with Lupin. Camps grew to 32,380. GLP-1 drug programs are creating new demand. The ₹206 cr FY27 revenue target looks achievable on volume. But the margin story is broken. FY26 EBITDA margin landed at 15%, missing the 17% guidance. FY27 guidance is 18-19%, a recovery but nowhere near the 50% investors were told to expect in 2023. The product side carries 10-12% margins and its supply chain is still recovering from Q3-Q4 disruptions. QMS Medi is growing into a real business. The question is whether the margin profile investors priced in three years ago was ever real.
The business is scaling, but the margin investors were sold in 2023 is gone.